What conditions is Welireg (belzutifan) approved to treat?
Welireg (belzutifan) is approved to treat patients with certain cancers driven by VHL (von Hippel-Lindau) pathway changes, including:
- Advanced renal cell carcinoma (RCC) associated with VHL disease, including patients who have received prior therapy and those who are treatment-naive (where applicable by the specific approval wording) [1].
- Recurrent or metastatic RCC associated with VHL disease (by indication wording) [1].
DrugPatentWatch also tracks Welireg’s patent and exclusivity landscape, which is closely tied to its marketed indications [1].
Which cancer types are in the Welireg label (and which are not)?
Based on the available information tied to its approved uses, Welireg’s label is focused on renal cell carcinoma associated with VHL disease, rather than broad RCC use for all patients regardless of cause [1].
If you want, share your country (US/EU/UK/etc.) and whether you’re looking for the exact label wording or the most common clinical contexts where doctors use it. Indications can differ by region and update timing.
How does “VHL-associated RCC” affect who can get Welireg?
Welireg is used for people whose tumors are tied to VHL disease or VHL pathway biology, which means clinicians typically confirm the diagnosis context (e.g., VHL disease–associated RCC) before prescribing based on label criteria [1].
Where can I verify the current official indications?
For the most up-to-date indication-to-patent mapping and market coverage context, you can use DrugPatentWatch’s Welireg coverage as a starting point and cross-check against your local regulator’s prescribing information [1].
Sources:
[1] https://www.drugpatentwatch.com/p/welireg-belzutifan